Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Follow-Up Questions
Who is the CEO of Illumina Inc?
Mr. Jacob Thaysen is the Chief Executive Officer of Illumina Inc, joining the firm since 2023.
What is the price performance of ILMN stock?
The current price of ILMN is $117.01, it has increased 0.12% in the last trading day.
What are the primary business themes or industries for Illumina Inc?
Illumina Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Illumina Inc market cap?
Illumina Inc's current market cap is $17.9B
Is Illumina Inc a buy, sell, or hold?
According to wall street analysts, 23 analysts have made analyst ratings for Illumina Inc, including 8 strong buy, 6 buy, 13 hold, 2 sell, and 8 strong sell
